MassDevice Archives - Page 406 of 587 - Medical Design Sourcing

Aerin Medical touts study of nasal airway obstruction treatment

[Image from Aerin Medical]Aerin Medical today touted results from a three-month study of its VivAer treatment for nasal airway obstruction (NAO).

Sunnyvale, Calif.-based Aerin’s VivAer was studied in the VATRAC trial, with results published by the International Forum of Allergy and Rhinology.

According to a news release, the study confirmed the safety and efficacy of VivAer in treating NAO caused by nasal valve collapse (NVC). Those treated with VivAer showed significant improvement in nasal obstruction symptoms compared to the control group.

The multi-center, prospective, single-blinded, randomized, sham-controlled trial enrolled 117 patients with extreme or severe NAO with NVC as a primary or significant contributor to their symptoms. Patients were randomized to undergo in-office treatment with VivAer or an in-office sham procedure that replicated the treatment experience without delivery therapeutic radiofrequency energy.

VATRAC met its prim…

Iradimed appoints chief financial, operating officer

Iradimed (NSDQ:IRMD) today said it has appointed Chris Scott as chief financial and operating officer, effective immediately.

Scott has served as the Winter Springs, Fla.-based company’s chief financial officer since December 2013. In his new role, Scott will be responsible for providing leadership and oversight in certain operations functions of the MRI-compatible medical device developer company, including customer service, supply chain, manufacturing, regulatory and quality affairs.

The leadership change comes a year after the company’s former president and CEO Leslie McDonnell resigned and Roger Susi took over.

AngioDynamics rises on Street-beating Q4 revenues

AngioDynamics (NSDQ:ANGO) shares ticked up this morning on fourth-quarter results that beat the consensus revenue forecast.

The Latham, N.Y.-based peripheral artery disease (PAD) treatment developer posted losses of -$19.5 million, or -51¢ per share, on sales of $76.8 million for the three months ended May 31, 2021, for an 87.6% bottom-line gain on sales growth of 31.7%.

Adjusted to exclude one-time items, earnings per share were even at $0, equaling the projections made on Wall Street, where analysts were looking for sales of $72.7 million.

“The AngioDynamics team demonstrated excellent performance, resilience, and strong execution in what was a uniquely challenging year. We saw the pressure from COVID-19 gradually alleviate over the course of the year, and our business is now trending close to normalized run rates. During fiscal 2021, we took significant steps forward in our transformation into a growth-oriented, technology-driven company, building on …

Glytec appoints first chief medical officer

Cloud-based insulin management software developer Glytec announced today that it appointed Dr. Jordan Messler as chief medical officer.

Messler’s responsibilities as the company’s first-ever CMO include spearheading continuous improvement initiatives for Glytec’s clinical strategy and product development.

Get the full story at our sister site, Drug Delivery Business News.

GE turns to AI to boost MR for cancer therapy planning

GE Healthcare (NYSE:GE) recently announced that it has collaborated with Spectronic Medical to make AI-based software for more precise cancer treatment planning.

Spectronic Medical’s AI-based software can be used with GE Healthcare’s AIR Recon DL technology for MR-only based radiotherapy planning for better soft tissue differentiation than traditional CT.

Get the full story on our sister site, MassDevice.

Versapor® RC Membranes: The next generation of venting materials

As the world leader in the design and production of membranes, filtration devices, and separation systems, Pall Corporation supplies products to nearly every industry in the world. Founded in 1946, Pall Corporation has set the standard for filtration solutions for 75 years and counting. Our customers have relied on us for their most sophisticated applications in diagnostics, healthcare, biopharmaceuticals, municipal water, aerospace, hydraulics, industrial fluid processing, and more. Our extensive portfolio of membrane materials offers you flexibility and peace of mind knowing that you will find the right solution for your application needs.

Pall Corporation has developed the highest quality of microporous membranes and materials for filtration, separation, and purification to help optimize product performance and minimize development costs. Whether you are choosing from our standard product portfolio, requesting a modification on an existing product, or explo…

Nephros acquires GenArraytion pathogen detection tech

Nephros (Nasdaq: NEPH) announced today that it has acquired almost all of the assets of Rockville, Md.–based GenArraytion.

The financial terms of the deal were not disclosed.

Nephros officials said the purchase will give their company access to a host of GenArraytion proprietary assays, multiplexing technology, and selection methods for detecting waterborne pathogens and other microorganisms through polymerase chain reaction (PCR) technology.

South Orange, N.J.–based Nephros provides filtration and pathogen detection solutions to the medical and commercial markets.

“The strategic acquisition of GenArraytion further cements our position in the emerging PCR testing market for waterborne pathogens, expanding our abilities to detect and mitigate the spread of infectious disease in premise plumbing,” Nephros CEO Andy Astor said in a news release.

“In addition to acquiring GenArraytion’s MultiFlex bioassays and other technologies, Dr. R. Paul Sch…

Court orders Hillrom to proceed with BardyDx acquisition

The Court of Chancery in the state of Delaware ordered Hillrom (NYSE:HRC) to complete its planned acquisition of BardyDx.

In March, Hillrom reversed course on the planned $375 million acquisition of Bardy Diagnostics and its Carnation Ambulatory Monitor, or CAM patch, claiming that closing conditions weren’t met.

Hillrom’s u-turn came in the wake of regional Medicare administrative contractor Novitas Solutions publishing significant rate cuts for external EKG monitoring, creating a setback for the technology, which could serve as an improvement over traditional Holter monitors.

The Delaware court’s opinion found that the Medicare rate cuts did not qualify as a material adverse event (MAE) that would allow Hillrom out of the deal. The opinion, given on July 9, noted that Hillrom did not prove that the new rates would not be changed.

Vice Chancellor Joseph Slights III ruled in favor of Bardy but did not order for Hillrom to provide…

Titan Medical appoints new CFO

Titan Medical (NSDQ:TMDI) announced today that it appointed Stephen Lemieux as its new chief financial officer.

Toronto-based Titan, a robotic surgical technology developer, said in a news release that current CFO Monique Delorme will leave the company, effective immediately. Delorme will remain in an advisory capacity through March 2022 to ensure a smooth transition.

“We would like to thank Monique for her contributions to Titan through a period of great change. Despite the COVID-19 pandemic, during the past 12 months we executed development and license agreements with Medtronic, built out and staffed a research and development facility in Chapel Hill, North Carolina and completed several financings, all of which would not have been possible without Monique’s support,” Titan president & CEO David McNally said in the release. “We are grateful for her commitment and tireless effort and consummate professionalism through this transition period.”

…

Sherlock Biosciences names new CEO

Sherlock Biosciences announced today it appointed Bryan Dechairo as its president and CEO and he will join the company’s board.

Dechairo will succeed co-founder Rahul Dhanda, who will continue to serve as a board member until the end of 2021, after which he will assume the role of strategic adviser in 2022.

He joins Cambridge, Mass.-based Sherlock Biosciences after most recently holding the position of executive VP of clinical development at Myriad Genetics. He was chief medical officer, chief scientific officer and senior VP of R&D at Assurex Health, which Myriad acquired in 2016.

Before Assurex Health, Dechairo held leadership positions at Medco Health Solutions, Pfizer and other diagnostic and therapeutics companies, according to a news release.

“I’m thrilled to be joining Sherlock at such a pivotal moment for the company,” Dechairo said in the release. “The past year’s successes are a remarkable testament to the commitment of this te…

Medtech veteran Martha Shadan joins CVRx board of directors

CVRx today said that medtech veteran Martha Shadan has joined its board of directors.

Shadan has more than 30 years of experience in the life sciences industry and has a long track record of success in commercializing medtech innovations in startups and large companies. She is currently the CEO of Miach Orthopedics. She has also held numerous leadership roles at Smith + Nephew, Rotation Medical, Zimmer Biomet, Covidien, Bristol Myers Squibb and Merck Millipore.

In addition to serving on Minneapolis-based CVRx’s board, Shadan is also a board member at AdvaMed, where she also chairs the diversity and inclusion committee and is a founding member of the Leadership Circle for the Women’s Executive Network (WEN). She also serves as a board advisor for several other companies.

“I am honored to serve on the CVRx board,” Shadan said in a news release. “As the developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of h…

BD announces two new directors for diabetes spinoff

BD (NYSE:BDX) announced today that it appointed David F. Melcher and Dr. Claire Pomeroy as directors of its diabetes spinoff.

Franklin Lakes, N.J.-based BD previously announced the separation of its diabetes care business into an independent, publicly traded company called NewCo.

Get the full story at our sister site, Drug Delivery Business News.